Association Between Plasma Melatonin and No-reflow
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,700
- 主要终点
- a change in the prevalence of no-reflow
研究概览
简要总结
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •a diagnosis of STEMI and needed PCI
排除标准
- •patients with cancer patients who used melatonin
结局指标
主要结局
a change in the prevalence of no-reflow
时间窗: mediately after percutaneous coronary intervention (PCI)
Thrombolysis in myocardial infarction (TIMI) flow grade of \<3 with a myocardial blush grade of 0-1 was defined as angiographic no-reflow
次要结局
- in-hospital major adverse cardiac or cerebrovascular events(up to 2 weeks after PCI)
- in-hospital complications(up to 2 weeks after PCI)
研究者
Chen Wei Ren, MD
Doctor
Chinese PLA General Hospital